Delgocitinib
- Generic Name
- Delgocitinib
- Brand Names
- Anzupgo
- Drug Type
- Small Molecule
- Chemical Formula
- C16H18N6O
- CAS Number
- 1263774-59-9
- Unique Ingredient Identifier
- 9L0Q8KK220
- Background
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
- Conditions
- Chronic Hand Eczema
- Interventions
- Other: Vehicle cream
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 360
- Registration Number
- NCT06004050
- Locations
- 🇨🇳
LEO Pharma Investigational Site, Zhenjiang, China
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT05486117
- Locations
- 🇩🇪
LEO Investigational Site, Hamburg, Germany
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 98
- Registration Number
- NCT05355818
- Locations
- 🇬🇧
LEO Pharma investigational site, Walsall, United Kingdom
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
- Conditions
- Frontal Fibrosing Alopecia
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 35
- Registration Number
- NCT05332366
- Locations
- 🇺🇸
LEO Investigational Site, Burlington, Massachusetts, United States
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 513
- Registration Number
- NCT05259722
- Locations
- 🇪🇸
LEO Pharma investigational site, Pontevedra, Spain
🇬🇧LEO Pharma Investigational Site, Nottingham, United Kingdom
A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo capsule
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT05050279
- Locations
- 🇬🇧
Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,, Leeds, United Kingdom
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 801
- Registration Number
- NCT04949841
- Locations
- 🇩🇰
LEO investigational Site, Copenhagen, Denmark
🇵🇱LEO Pharma Investigational Site, Rzeszów, Poland
🇬🇧LEO Investigational Sites, Redhill, Surrey, United Kingdom
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
- Conditions
- Chronic Hand Eczema
- Interventions
- Drug: Cream vehicle
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 487
- Registration Number
- NCT04871711
- Locations
- 🇬🇧
LEO Investigational Site, London, United Kingdom
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
- Conditions
- Chronic Hand Eczema
- Interventions
- Drug: Cream vehicle
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 473
- Registration Number
- NCT04872101
- Locations
- 🇪🇸
LEO Investigational Site, Sevilla, Spain
🇩🇪LEO Invesitgational Site, Hannover, Germany
Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT04807751
- Locations
- 🇩🇪
Bioskin Research Center Dermatology, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.